Alternate strategies to obtain mass balance without the use of radiolabeled compounds: Application of quantitative fluorine ( 19F) Nuclear Magnetic Resonance (NMR) spectroscopy in metabolism studies

Chemical Research in Toxicology

Volumn 25, Issue 3, 2012, Pages 572-583

  Mutlib, Abdul ^a   Espina, Robert ^a   Atherton, James ^a   Wang, Jianyao ^a   Talaat, Rasmy ^a   Scatina, JoAnn ^a   Chandrasekaran, Appavu ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG METABOLITE; FLUORINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; FECES; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUANTITATIVE STUDY; RADIOACTIVITY; RAT; URINE;

ANIMALS; CARBON RADIOISOTOPES; DOGS; DRUG DISCOVERY; FECES; FLUORINE COMPOUNDS; FLUORINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 84863338113     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx2005629     Document Type: Article

References (53)

1. Mutlib, A. E., and Shockcor, J. P. (2003) Application of LC/MS, LC/NMR and Stable Isotopes in Identifying and Characterizing Metabolites, in Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Lee, J. S., Obach, R. S., and Fisher, M. B., Eds) pp 33-86 Fontis Media and Marcel Dekker, New York, NY.
2. Prestgard, J. H. (2001) High resolution NMR of biomolecules. Lecture Notes Phys. 595, 426-434.
3. Holzgrabe., U., Deubner, R., Schollmayer, C., and Waibel, B. (2005) Quantitative NMR spectroscopy: Applications in drug analysis. J. Pharm. Biomed. Anal. 38, 806-812. (Pubitemid 41115786)
4. Pauli, G. F., Jaki, B., and Lankin, D. (2005) Quantitative 1H-NMR: Development and potential of a method for natural products analysis. J. Nat. Prod. 68, 133-149. (Pubitemid 40175949)
5. Pauli, G. F., Jaki, B. U., and Lankin, D. C. (2007) A routine experimental protocol for qHNMR illustrated with Taxol. J. Nat. Prod. 70, 589-595. (Pubitemid 46797861)
6. Pauli, G. F., Jaki, B. U., Lankin, D. C., Walter, J. A. (2008) Quantitative NMR of Bioactive Natural Products, in Bioactive Natural Products: Detection, Isolation and Structural Determination (Colgate, S. M., and Molyneux, R. J., Eds) pp 113-141, CRC Press, Boca Raton, FL.
7. Bernadou, J., Armand, J. P., Lopez, A., Malet-Martino, M. C., and Martino, R. (1985) Complete urinary excretion profile of 5- fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance. Clin. Chem. 31, 846-848. (Pubitemid 16140534)
8. Gilard, V., Malet-Martino, M. C., De Forni, M., Niemeyer, U., Ader, J. C., and Martino, R. (1993) Determination of the urinary excretion of ifosfamide and its phosporated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy. Cancer Chemother. Pharmacol. 31, 387-394. (Pubitemid 23045652)
9. Malet-Martino, M. C., and Martino, R. (1992) Magnetic resonance spectroscopy: a powerful tool for drug metabolism studies. Biochimie 74, 785-800.
10. Le Belle, J. E., Harris, N. G, Williams, S. R., and Bhakoo, K. K. (2002) A comparison of cell and tissue extraction techniques using high-resolution 1H-NMR spectroscopy. NMR Biomed. 15, 37-44. (Pubitemid 34177166)
11. Lenz, E. M., Wilson, I. D., Wright, B., Partridge, E. A., Rodgers, C. T., Haycock, P. R., Lindon, J. C., and Nicholson, J. K. (2002) A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. J. Pharm. Biomed. Anal. 28, 31-43. (Pubitemid 34171644)
12. Skordi, E., Wilson, I. D., Lindon, J. C., and Nicholson, J. K. (2004) Characterization and quantification of metabolites of racemic ketoprofen excreted in urine following oral administration to man by 1H-NMR spectroscopy, directly coupled HPLC-MS and HPLC-NMR, and circular dichroism. Xenobiotica 24, 1075-1089. (Pubitemid 40070107)
13. Martino, R., Gilard, V., Desmoulin, F., and Malet-Martino, M. (2005) Fluorine-19 or phosphorus-31 NMR spectroscopy: A suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs. J. Pharm. Biomed. Anal. 38, 871-891. (Pubitemid 41115794)
14. Moazzami, A. A., Anderson, R. E., and Kamal-Eldin, A. (2007) Quantitative NMR analysis of a sesamin catechol metabolite in human urine. J. Nutr. 137, 940-944. (Pubitemid 46596891)
15. Silvestre, V., Goupry, S., Trierweiler, M., Robins, R., and Akoka, S. (2001) Determination of substrate and product concentrations in lactic acid bacterial fermentations by proton NMR using the ERETIC method. Anal. Chem. 73, 1862-1868. (Pubitemid 32862454)
16. Henderson, T. J. (2002) Quantitative NMR spectroscopy using coaxial inserts containing a reference standard: Purity determinations for military nerve agents. Anal. Chem. 74, 191-198.
17. Hays, P. A. (2005) Proton nuclear magnetic resonance spectroscopy (NMR) methods for determining the purity of reference drug standards and illicit forensic drug seizures. J. Forensic Sci. 50, 1342-1360.
18. Lindon, J. C., Nicholson, J. K., and Holmes, E. (2005) NMR Spectroscopy of Biofluids, in Metabonomics in Toxicity Assessment (Robertson, D. G., and Lindon, J., Eds.) pp 105-172, Taylor and Francis, Boca Raton, FL.
19. Lindon, J. C., Holmes, E., and Nicholson, J. K. (2006) Recent developments and applications of NMR-based metabonomics. Bopuxue Zazhi 23, 101-127.
20. Wilson, I. D., and Nicholson, J. K. (2006) Metabonomics, in Comprehensive Medicinal Chemistry II (Taylor, J. B., and Triggle, D. J., Eds.) pp 989-1007, Elsevier, Oxford, U.K.
21. Evilia, R. F. (2001) Quantitative NMR spectroscopy. Anal. Lett. 34, 2227-2236.
22. Malz, F., and Jancke, H. (2005) Validation of quantitative NMR. J. Pharm. Biomed. Anal. 38, 813-823. (Pubitemid 41115787)
23. Burton, I. W., Quilliam, M. A., and Walter, J. A. (2005) Quantitative 1H-NMR with external standards: Use in preparation of calibration solutions for algal toxins and other natural products. Anal. Chem. 77, 3123-3131. (Pubitemid 40695467)
24. U. S. Food and Drug Administration (2008) Guidance for Industry Safety Testing of Drug Metabolites, Center for Drug Evaluation and Research (CDER).
25. International Conference on Harmonization (2009) Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2).
26. Dear, G. J., Roberts, A. D., Beaumont, C., and North, S. E. (2008) Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J. Chromatogr., B 876, 182-190.
27. Espina, R., Yu, L., Wang, J., Tong, Z., Vashishta, S., Talaat, R., Scatina, J., and Mutlib, A. (2009) Nuclear magnetic resonanace spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: Implications in metabolites in safety testing. Chem. Res. Toxicol. 22, 299-310.
28. Vishwanathan, K., Babalola, K., Wang, J., Espina, R., Yu, L., Adedoyin, A., Talaat, R., Scatina, J., and Mutlib, A. (2009) Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: Addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 22, 311-322.
29. Clarke, N. J., Rindgen, D., Korfmacher, W. A., and Cox, K. A. (2001) Systemic LC/MS metabolite identification in drug discovery. Anal. Chem. 73, 430A-439A. (Pubitemid 32862353)
30. Zhang, H., Zhang, D., and Ray, K. (2003) A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J. Mass Spectrom. 38, 1110-1112. (Pubitemid 37407706)
31. Zhu, M., Ma, L., Zhang, D., Ray, K., Zhao, W., Humphreys, W. G., Skiles, G., Sanders, M., and Zhang, H. (2006) Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab. Dispos. 34, 1722-1733. (Pubitemid 44427475)
32. Prakash, C., Shaffer, C. L., and Tremaine, L. M. (2007) Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab. Lett. 1, 226-231.
33. Zhang, H., Zhu, M., Ray, K. L., Ma, L., and Zhang, D. (2008) Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun. Mass Spectrom. 22, 2082-2088. (Pubitemid 351956694)
34. Park, B. K., Kitteringham, N. R., and O'Meill, P. M. (2001) Metabolism of fluorine-containing drugs. Ann. Rev. Pharmacol. Toxicol. 41, 443-470. (Pubitemid 32385895)
35. Bachert, P. (1998) Pharmacokinetics using fluorine NMR in vivo. Prog. Nucl. Magn. Reson. Spectrosc. 33, 56.
36. Martino, R., Malet-Martino, M., and Gilard, V. (2000) Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr. Drug Metab. 1, 271-303.
37. Schneider, E., Bolo, N. R., Frederick, B., Wilkinson, B., Hirashima, F., Nassar, L., Lyoo, I. K., Koch, P., Jones, S., Hwang, J., Sung, Y., Villafuerte, R. A., Maier, G., Hsu, R., and Hashoian, R. (2006) Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole. J. Clin. Pharm. Ther. 31, 261-273. (Pubitemid 43873549)
38. Reid, D. G., and Murphy, P. S. (2008) Fluorine magnetic resonance in vivo: A powerful tool in the study of drug distribution and metabolism. Drug Discovery Today 13, 473-480.
39. Strauss, W. L., Layton, M. E., and Dager, S. R. (1998) Brain elimination half-life of fluvoxamine measured by 19-F magnetic resonance spectroscopy. Am. J. Psychiatr. 155, 380-384. (Pubitemid 28114896)
40. Griffiths, J. R., and Glickson, J. D. (2000) Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy. Adv. Drug Delivery Rev. 41, 75-89. (Pubitemid 30122950)
41. Mason, G. F., and Krystal, J. H. (2006) MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. NMR Biomed. 19, 690-701. (Pubitemid 44515613)
42. Wolf, W., Waluch, V., and Presant, C. A. (1998) Non-invasive 19-F NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamics studies. NMR Biomed. 11, 380-387. (Pubitemid 28547373)
43. Wolf, W., Presant, C. A., and Waluch, V. (2000) 19-F MRS studies of fluorinated drugs in humans. Adv. Drug Delivery Rev. 41, 56-74.
44. 19F-NMR and directly coupled HPLC-NMR-MS investigations into the metabolism of 2-bromo-4- trifluoromethylaniline in rat: a urinary excretion balance study without the use of radiolabelling. Xenobiotica 28, 373-388.
45. 19F-NMR spectroscopy and directly coupled HPLCNMR-MS. Xenobiotica 29, 77-91.
46. 19F-NMR spectroscopy, HPLC-MS/MS HPL-ICPMS and HPLC-NMR. Xenobiotica 36, 59-77.
47. Walker, D., Brady, J., Dalvie, D., Davis, J., Dowty, M., Duncan, J. N., Nedderman, A., Obach, R. S., and Wright, P. (2009) A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem. Res. Toxicol. 22, 1653-1662.
48. Chen, H., Chen, W., Gan, L., and Mutlib, A. E. (2003) Metabolism of (S-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H) -quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metab. Dispos. 31, 122-132. (Pubitemid 36735266)
49. Warren, R. J., Zarembo, J. E., Staiger, D. B., and Post, A. (1976) Quantitative NMR analysis of a four-component mixture of phenylglycine derivatives. J. Pharm. Sci. 65, 738-740.
50. Groen, D., Metternich, H. J., and Schoenfelder, W. (1998) Quantitative NMR-spectroscopic analysis of the compounds of glycerol esters of fatty acids. Lipid 100, 64-69.
51. Rizzo, V., and Pinciroli, V. (2005) Quantitative NMR in synthetic and combinatorial chemistry. J. Pharm. Biomed. Anal. 38, 851-857. (Pubitemid 41115791)
52. Diehl, B. W. K., Malz, F., and Holzgrabe, U. (2007) Quantitative NMR spectroscopy in the quality evaluation of active pharmaceutical ingredients and excipients. Spec. Eur. 19, 15-19. (Pubitemid 350074081)
53. Mutlib, A. E. (2008) Application of stable isotope-labeled compounds in metabolism and in metabolism-mediated toxicity studies. Chem. Res. Toxicol. 21, 1672-1689.